Real-world evidence on clearing hrHPV infection
Real-world studies can provide better understanding of how a treatment
is used in routine clinical practice. Real-world data enable a greater
appreciation of the true efficacy and safety profile of a treatment in
the real world, by reflecting the actual diagnosis, treatment process
and health status of patients under real conditions. In a recent
real-world study of 506 patients at nine hospitals in seven Chinese
provinces (Figure S1), 69.57% of hrHPV-positive patients became
hrHPV-negative following treatment (Table 2).24 These
real-world data are in agreement with the results of our two previous
independent parallel clinical studies.13 This
real-world study further revealed the diversity among different hrHPV
subtypes. The clearance rates of hrHPV subtypes 16, 18, and 52 were
77.78%, 85.37%, and 61.11%, respectively (Table 2). The real-world
study also revealed there was no significant side effect during the
treatment and all follow-ups, beside mild vaginal itch occasionally
observed during treatments24, which is in line with
our previous clinical studies13-14. This study further
supports the safety and efficacy of REBACIN® as a
non-invasive clinical regimen for the clearance of persistent hrHPV
infections.24